Development of Neuromedin Receptor 2 antagonists as Novel Analgesics
NINDS - National Institute of Neurological Disorders and Stroke
About This Grant
Abstract Chronic pain affects millions of individuals globally, profoundly impacting their quality of life and imposing a significant burden on healthcare systems. While opioids have been the gold standard for treating moderate to severe pain, their serious adverse effects, such as dependency and tolerance, limit their clinical utility. Consequently, there is a critical need to explore new therapeutic targets for more effective and safer pain management strategies. Neuromedin U (NMU) is a neuropeptide that modulates various physiological functions, including pain perception, through its interaction with Neuromedin U Receptor 2 (NMUR2). Emerging evidence suggests that NMUR2 plays a crucial role in the transmission and modulation of pain signals within the central nervous system, and blocking this receptor could potentially alleviate pain. This proposal aims to establish a comprehensive structure-activity relationship (SAR) for two chemical series of NMUR2 antagonists, with the goal of optimizing their potency, selectivity, and drug-like properties. Upon completion of this project, we aim to provide structure-activity relationship data for compound optimization, early-stage ADME and pharmacokinetic information, laying the foundation for developing NMUR2 targeting tool compounds and drug candidates for chronic pain treatment.
Grant Summary
Development of Neuromedin Receptor 2 antagonists as Novel Analgesics is a NINDS - National Institute of Neurological Disorders and Stroke grant providing up to $231K for university, nonprofit, healthcare org. Applications are due 2028-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $231K
2028-03-31
- 1Confirm your organization is eligible for Development of Neuromedin Receptor 2 antagonists as Novel Analgesics from NINDS - National Institute of Neurological Disorders and Stroke, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NINDS - National Institute of Neurological Disorders and Stroke before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NINDS - National Institute of Neurological Disorders and Stroke's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Development of Neuromedin Receptor 2 antagonists as Novel Analgesics: Frequently Asked Questions
Who is eligible for the Development of Neuromedin Receptor 2 antagonists as Novel Analgesics?
Development of Neuromedin Receptor 2 antagonists as Novel Analgesics is offered by NINDS - National Institute of Neurological Disorders and Stroke and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Development of Neuromedin Receptor 2 antagonists as Novel Analgesics provide?
Development of Neuromedin Receptor 2 antagonists as Novel Analgesics provides up to $231K per award from NINDS - National Institute of Neurological Disorders and Stroke. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Development of Neuromedin Receptor 2 antagonists as Novel Analgesics deadline?
Applications for Development of Neuromedin Receptor 2 antagonists as Novel Analgesics are due 2028-03-31 (open). Because deadlines can change, verify the date with the funder, NINDS - National Institute of Neurological Disorders and Stroke, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Development of Neuromedin Receptor 2 antagonists as Novel Analgesics?
To apply for Development of Neuromedin Receptor 2 antagonists as Novel Analgesics, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NINDS - National Institute of Neurological Disorders and Stroke.